| Name | Title | Contact Details |
|---|
Insightra Medical is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MiraVista is a new behavioral health treatment center opening April 2021 in the former Providence Hospital in Holyoke, MA. The newly renovated center will initially provide adult psychiatric and addiction treatment and will expand capacity to include child and adolescent services by the end of the year. Our mission is to provide compassionate, effective, sustainable care for those suffering from psychiatric distress and substance abuse. We are committed to helping fill the critical need for quality behavioral care in the Pioneer Valley and are excited to open our doors this Spring.
Compassus is a national leader in providing high-quality, compassionate, person-centered care to individuals wherever they call home. Our continuum of integrated home-based care, including home health infusion therapy palliative and hospice care ensures patients and their families have the support they need to address current and future health needs. Partnering with Compassus brings peace of mind to patients, caregivers, and health care providers. Our team members work collaboratively to manage patient conditions and meet goals of care alongside referring physicians, health systems, long-term care partners, and family members. Our value is in the compassion and expertise of our teams, which act as an extension of patients` existing care teams. We believe everyone who interacts with us should experience our individualized `Care for who` I am philosophy, from the care services we provide to patients and families to how we interact with our partners and one another.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Were for youth development, healthy living and social responsibility.